mp.weixin.qq.com·· 21 hours agoPickScore66
Leaked Moderna Cancer Vaccine Phase III Data Show 42% Lower Recurrence or Death Risk, Shares Fall 26% Intraday
In brief
Phase III data for Moderna's cancer vaccine showed a 42% reduction in the risk of recurrence or death, and the leak of the data triggered a sharp stock decline. On October 22 local time, Moderna shares fell as much as 26% intraday before closing down 17.57%, while partner Merck closed down 1.76%.
Why it matters
Phase III data show a 42% risk reduction and an intraday stock drop of 26%, letting readers compare clinical results with market reaction.
Source: mp.weixin.qq.com · mp.weixin.qq.com